Tags » Sorafenib

Pipeline Series: Renal Cell Carcinoma - Cancer Therapy Advisor

In the last decade, the U.S. Food and Drug Administration (FDA) has approved a variety of kinase inhibitors, including sorafenib, temsirolimus, everolimus, sunitinib, pazopanib, and axitinib—all angiogenesis inhibitor— for the treatment of patients with advanced renal cell carcinoma (RCC). 157 more words

Kidney Cancer

Restrictive global governance system affects public health

“The present global health crisis is not primarily one of disease, but of governance…” noted Ilona Kickbusch in a January-February issue of the Canadian Journal of Public Health . 851 more words

Public Health

Generic Sorafenib Nexavar Cancer Medicine

Sorafenib is a drug approved for the treatment of kidney cancer, liver cancer and thyroid carcinoma. The actual Generic Drug and base Medicine SORAFENIB are sold internationally under the most common marketing brand NEXAVAR. 293 more words

Cancer Medicine